See the DrugPatentWatch profile for Cimzia
Cimzia 200 mg is a brand-name prescription medication used to treat certain autoimmune conditions [1]. It is an injection containing certolizumab pegol, a tumor necrosis factor (TNF) blocker [1][2].
What conditions does Cimzia 200 mg treat?
Cimzia 200 mg is FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) in adults, active psoriatic arthritis (PsA) in adults, and moderate to severe ankylosing spondylitis (AS) in adults [1][3]. It is also indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [1][3]. Cimzia is typically used when other treatments have not been effective [1].
How does Cimzia 200 mg work?
Cimzia (certolizumab pegol) is a biologic medication that works by targeting and blocking tumor necrosis factor-alpha (TNF-alpha) [2]. TNF-alpha is a protein that plays a significant role in inflammation within the body. By inhibiting TNF-alpha, Cimzia helps to reduce inflammation, pain, and joint damage associated with conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2][4]. For plaque psoriasis, it reduces inflammation and the characteristic skin lesions [3].
How is Cimzia 200 mg administered?
Cimzia 200 mg is administered as a subcutaneous injection [1]. It can be given by a healthcare professional or self-administered by a patient after proper training [1]. Dosing and frequency depend on the specific condition being treated [1]. For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, the typical starting dose is 400 mg (given as two 200 mg injections) at weeks 0, 2, and 4, followed by a maintenance dose of 200 mg every two weeks [1]. For plaque psoriasis, the starting dose is 400 mg (two 200 mg injections) at weeks 0, 2, and 4, followed by 200 mg every two weeks, or 400 mg every four weeks [1].
What are the potential side effects of Cimzia?
Common side effects of Cimzia can include infections (such as upper respiratory tract infections, urinary tract infections, and nasopharyngitis), rash, itching, headache, and back pain [1]. Cimzia can also increase the risk of serious infections, including tuberculosis (TB), and may reactivate a previous hepatitis B infection [1][5]. Other serious side effects may include allergic reactions, heart failure, nervous system problems, and certain types of cancer [1]. Patients should discuss their medical history and any concerns with their doctor before starting Cimzia [1].
When does the patent for Cimzia expire?
The patent protection for Cimzia has been a subject of legal challenges. Information regarding specific patent expiry dates and ongoing litigation can be found through resources tracking pharmaceutical patents [6]. Companies often seek to extend patent exclusivity through various means, and the exact timeline for generic or biosimilar entry can be complex [6].
Are there alternative treatments for conditions treated by Cimzia?
Yes, there are alternative treatments available for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [4]. These may include other classes of medications such as conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), other biologic DMARDs that target different pathways (like IL-17 or IL-23 inhibitors), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and topical treatments [4][7]. The choice of treatment depends on the specific condition, its severity, individual patient factors, and response to previous therapies [4][7].
Who manufactures Cimzia?
Cimzia is manufactured by UCB [1].
Sources:
[1] https://www.cimzia.com/
[2] https://www.drugpatentwatch.com/drug/certolizumab-pegol
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125265s116,125265s117lbl.pdf
[4] https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
[5] https://www.drugpatentwatch.com/drugs/certolizumab-pegol/important-safety-information
[6] https://www.drugpatentwatch.com/
[7] https://www.niams.nih.gov/health-topics/psoriatic-arthritis